Weil Company’s GSK GSK Stock Holding History

Weil Company’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,256	Closed	-$120K	–	200
2019 Q3	$120K	Sell	2,256 -2,800	-55%	-$144K	0.09%	124
2019 Q2	$253K	Hold	5,056	–	–	0.21%	90
2019 Q1	$264K	Hold	5,056	–	–	0.22%	85
2018 Q4	$241K	Hold	5,056	–	–	0.22%	85
2018 Q3	$254K	Hold	5,056	–	–	0.21%	89
2018 Q2	$255K	Buy	+5,056	New	+$255K	0.22%	82

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Weil Company's GSK Position: Q4 2019 in Review

Weil Company sold out of GSK (GSK) in Q4 2019, closing a stake of 2,256 shares — an estimated $120K sold.

Weil Company first reported a position in GSK in Q2 2018 and held it in 6 quarters. The position peaked at $264K in Q1 2019. 894 funds tracked by Wall St. Rank hold GSK as of Q4 2019.

Weil Company reported no remaining GSK position as of Q4 2019 after selling out during the quarter.
Weil Company sold 2,256 GSK shares in Q4 2019, an estimated $120K.
Weil Company first reported a position in GSK in Q2 2018 and held it in 6 quarters.
Weil Company's GSK position peaked at $264K in Q1 2019.
894 funds tracked by Wall St. Rank held GSK as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.